Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Israel in February 2020 and spread from then. In December 2020, the FDA approved an emergency use authorization of the Pfizer-BioNTech vaccine, and on 20 December, an immunization campaign began among adults in Israel. We charac...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/10/1663 |
| _version_ | 1797469685491433472 |
|---|---|
| author | Ravit Bassal Lital Keinan-Boker Dani Cohen Ella Mendelson Yaniv Lustig Victoria Indenbaum |
| author_facet | Ravit Bassal Lital Keinan-Boker Dani Cohen Ella Mendelson Yaniv Lustig Victoria Indenbaum |
| author_sort | Ravit Bassal |
| collection | DOAJ |
| description | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Israel in February 2020 and spread from then. In December 2020, the FDA approved an emergency use authorization of the Pfizer-BioNTech vaccine, and on 20 December, an immunization campaign began among adults in Israel. We characterized seropositivity for IgG anti-spike antibodies against SARS-CoV-2 between January 2020 and July 2021, before and after the introduction of the vaccine in Israel among adults. We tested 9520 serum samples, collected between January 2020 and July 2021. Between January and August 2020, seropositivity rates were lower than 5.0%; this rate increased from September 2020 (6.3%) to April 2021 (84.9%) and reached 79.1% in July 2021. Between January and December 2020, low socio-economic rank was an independent, significant correlate for seropositivity. Between January and July 2021, the 40.00–64.99-year-old age group, Jews and others, and residents of the Northern district were significantly more likely to be seropositive. Our findings indicate a slow, non-significant increase in the seropositivity rate to SARS-CoV-2 between January and December 2020. Following the introduction of the Pfizer-BioNTech vaccine in Israel, a significant increase in seropositivity was observed from January until April 2021, with stable rates thereafter, up to July 2021. |
| first_indexed | 2024-03-09T19:24:43Z |
| format | Article |
| id | doaj.art-3abcfb9b157c4faaac435e878fb5169f |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T19:24:43Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-3abcfb9b157c4faaac435e878fb5169f2023-11-24T03:03:52ZengMDPI AGVaccines2076-393X2022-10-011010166310.3390/vaccines10101663Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021Ravit Bassal0Lital Keinan-Boker1Dani Cohen2Ella Mendelson3Yaniv Lustig4Victoria Indenbaum5Israel Center for Disease Control, Ministry of Health, Gertner Institute, Chaim Sheba Medical Center, Tel-Hashomer 52621, IsraelIsrael Center for Disease Control, Ministry of Health, Gertner Institute, Chaim Sheba Medical Center, Tel-Hashomer 52621, IsraelDepartment of Epidemiology and Preventive Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, IsraelDepartment of Epidemiology and Preventive Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, IsraelDepartment of Epidemiology and Preventive Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, IsraelCentral Virology Laboratory, Public Health Services, Ministry of Health, Chaim Sheba Medical Center, Tel Hashomer 52621, IsraelSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in Israel in February 2020 and spread from then. In December 2020, the FDA approved an emergency use authorization of the Pfizer-BioNTech vaccine, and on 20 December, an immunization campaign began among adults in Israel. We characterized seropositivity for IgG anti-spike antibodies against SARS-CoV-2 between January 2020 and July 2021, before and after the introduction of the vaccine in Israel among adults. We tested 9520 serum samples, collected between January 2020 and July 2021. Between January and August 2020, seropositivity rates were lower than 5.0%; this rate increased from September 2020 (6.3%) to April 2021 (84.9%) and reached 79.1% in July 2021. Between January and December 2020, low socio-economic rank was an independent, significant correlate for seropositivity. Between January and July 2021, the 40.00–64.99-year-old age group, Jews and others, and residents of the Northern district were significantly more likely to be seropositive. Our findings indicate a slow, non-significant increase in the seropositivity rate to SARS-CoV-2 between January and December 2020. Following the introduction of the Pfizer-BioNTech vaccine in Israel, a significant increase in seropositivity was observed from January until April 2021, with stable rates thereafter, up to July 2021.https://www.mdpi.com/2076-393X/10/10/1663SARS-CoV-2antibodiesIsraelNational Sera BankReceptor binding domainseroprevalence |
| spellingShingle | Ravit Bassal Lital Keinan-Boker Dani Cohen Ella Mendelson Yaniv Lustig Victoria Indenbaum Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021 Vaccines SARS-CoV-2 antibodies Israel National Sera Bank Receptor binding domain seroprevalence |
| title | Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021 |
| title_full | Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021 |
| title_fullStr | Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021 |
| title_full_unstemmed | Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021 |
| title_short | Estimated Infection and Vaccine Induced SARS-CoV-2 Seroprevalence in Israel among Adults, January 2020–July 2021 |
| title_sort | estimated infection and vaccine induced sars cov 2 seroprevalence in israel among adults january 2020 july 2021 |
| topic | SARS-CoV-2 antibodies Israel National Sera Bank Receptor binding domain seroprevalence |
| url | https://www.mdpi.com/2076-393X/10/10/1663 |
| work_keys_str_mv | AT ravitbassal estimatedinfectionandvaccineinducedsarscov2seroprevalenceinisraelamongadultsjanuary2020july2021 AT litalkeinanboker estimatedinfectionandvaccineinducedsarscov2seroprevalenceinisraelamongadultsjanuary2020july2021 AT danicohen estimatedinfectionandvaccineinducedsarscov2seroprevalenceinisraelamongadultsjanuary2020july2021 AT ellamendelson estimatedinfectionandvaccineinducedsarscov2seroprevalenceinisraelamongadultsjanuary2020july2021 AT yanivlustig estimatedinfectionandvaccineinducedsarscov2seroprevalenceinisraelamongadultsjanuary2020july2021 AT victoriaindenbaum estimatedinfectionandvaccineinducedsarscov2seroprevalenceinisraelamongadultsjanuary2020july2021 |